Apremilast clinical trials
Also written Otezla, CC-10004 and AMG 407.
How each study uses apremilast is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the apremilast studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- 21 Mar 2014 · OTEZLA · NDA 205437 (FDA, Drugs@FDA)
- European Union
- 15 Jan 2015 · Otezla · EMEA/H/C/003746 (EMA)
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
117 studies that test it; most in 2010 (15)
| Year | Studies |
|---|---|
| 2005 | 1 |
| 2006 | 1 |
| 2007 | 2 |
| 2008 | 5 |
| 2009 | 5 |
| 2010 | 15 |
| 2012 | 5 |
| 2013 | 2 |
| 2014 | 3 |
| 2015 | 5 |
| 2016 | 8 |
| 2017 | 11 |
| 2018 | 12 |
| 2019 | 12 |
| 2020 | 6 |
| 2021 | 2 |
| 2022 | 6 |
| 2023 | 5 |
| 2024 | 3 |
| 2025 | 1 |
| 2026 | 7 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 48 · Other 69
Amgen (46) · Icahn School of Medicine at Mount Sinai (3) · Yale University (2) · Tufts Medical Center (2) · Psoriasis Treatment Center of Central New Jersey (2) · University Hospitals Cleveland Medical Center (2) · Oregon Health and Science University (2) · Derm Research, PLLC (2)
Often tested with
Tested in the same studies.
Etanercept (4) · Methotrexate (4) · Cyclosporine (3) · Adalimumab (3) · Secukinumab (3) · Ustekinumab (3) · Remdesivir (2) · Imatinib (2)
Related medicines
As reviewed, each with the page that says it.
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Tested against it · 1 phase 3 study under way
Apremilast is the comparator. A study of two new drugs counts under both.
- 1Deucravacitinib · Bristol-Myers Squibb
Reaching primary completion within a year · 4, 1 in phase 3
Studies that test apremilast, phase 3 first.
- Dec 2026Randomized Double Blind Controlled Trial Comparing the Safety and Efficacy of Apremilast Versus Placebo in Severe Forms of Recurrent Aphthous StomatitisPhase 3 · University Hospital, Rouen
- Dec 2026Apremilast and Adalimumab in Psoriatic Arthritis PatientsNot applicable · Tanta University
- Jan 2027Comparing the Extent to Which Apremilast is Made Available in the Body After Administration as an Extended-release or Immediate-release FormulationPhase 1 · Amgen
- Jan 2027Human Laboratory Study of Apremilast for Alcohol Use DisorderPhase 2 · National Institute on Alcohol Abuse and Alcoholism (NIAAA)
Studies
Open first, then newest update. How each study uses apremilast is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 117
- A Study of Apremilast in Children With Oral Ulcers Associated With Behçet's Disease or Juvenile Psoriatic ArthritisRecruitingPhase 3AmgenNCT05767047Written as Apremilast
- Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired PneumoniaRecruitingPhase 3UMC UtrechtNCT02735707Written as Apremilast
- Comparing the Extent to Which Apremilast is Made Available in the Body After Administration as an Extended-release or Immediate-release FormulationNot yet recruitingPhase 1AmgenNCT07908641Written as Apremilast XR
- Phase 2 Study of Apremilast in Women and Men With Alcohol Use DisorderRecruitingPhase 2Yale UniversityNCT07029529Written as Apremilast 60mg
- Apremilast Pediatric Study in Children With Active Juvenile Psoriatic ArthritisRecruitingPhase 3AmgenNCT04804553Written as Apremilast
- Apremilast Added to Antihistamines in Chronic UrticariaEnrolling by invitationPhase 2Rashid Latif Medical CollegeNCT07850843Written as Apremilast
- Apremilast and Adalimumab in Psoriatic Arthritis PatientsNot yet recruitingNot applicableTanta UniversityNCT07398651Written as Apremilast
- Apremilast Pediatric Study in Children With Active Oral Ulcers Associated With Behçet's DiseaseRecruitingPhase 3AmgenNCT04528082Written as Apremilast
- Utilization of a Microdevice for Psoriasis and Atopic DermatitisNot yet recruitingPhase 4University of California, San FranciscoNCT07352566Written as Apremilast
- Methotrexate Versus Apremilast for Pruritus in PsoriasisNot yet recruitingPhase 4Zarmeen KhawarNCT07432386Written as Apremilast
- Human Laboratory Study of Apremilast for Alcohol Use DisorderRecruitingPhase 2National Institute on Alcohol Abuse and Alcoholism (NIAAA)NCT07325266Written as Apremilast
- Randomized Double Blind Controlled Trial Comparing the Safety and Efficacy of Apremilast Versus Placebo in Severe Forms of Recurrent Aphthous StomatitisRecruitingPhase 3University Hospital, RouenNCT04227314Written as Apremilast
- To Check Comparison of Apremilast and Methotrexate Efficacy in Patients With Moderate to Severe Plaque Psoriasis Presented to Tertiary Care HospitalRecruitingEarly Phase 1Syeda Sana ZamanNCT07337434Written as Apremilast
- Effects of Treatment With Biological Agents on Vascular and Cardiac Function in PsoriasisRecruitingPhase 4University of AthensNCT02144857Written as Apremilast
- Impact of Tapering Immunosuppressants on Maintaining Minimal Disease Activity in Adult Subjects With Psoriatic ArthritisRecruitingPhase 3University of Erlangen-Nürnberg Medical SchoolNCT04610476Written as Apremilast
- A Study of Apremilast in Pediatric Participants in Children With Mild to Moderate Plaque PsoriasisCompletedPhase 3AmgenNCT06088199Written as Apremilast
- A Study to Assess the Efficacy and Safety of Apremilast in Japanese Pediatric Participants With Moderate to Severe Plaque PsoriasisCompletedPhase 3AmgenNCT05565560Written as Apremilast
- Efficacy, Safety, and Tolerability Study of Apremilast to Treat Early Oligoarticular Psoriatic Arthritis.CompletedPhase 4AmgenNCT03747939Written as Apremilast (CC-10004)
- Comparative Efficacy of Apremilast and Acitretin in Moderate-to-Severe Hidradenitis SuppurativaCompletedPhase 4Hayat Abad Medical Complex, PeshawarNCT07708480Written as Apremilast
- Apremilast for Erythema MultiformeCompletedPhase 2Robert MichelettiNCT05875714Written as Apremilast
See all 117 studies that test apremilast →
Given beside what is tested · 5 — apremilast is usual care or a partner of the new treatment
- [18F]PF-06445974 to Image PDE4B in Major Depressive Disorder Using PETRecruitingPhase 1National Institute of Mental Health (NIMH)NCT05703685Written as Apremilast
- Study of Subcutaneous Risankizumab Injection Compared to Oral Apremilast Tablets to Assess Change in Disease Activity And Adverse Events in Adult Participants With Moderate Plaque Psoriasis Who Are Candidates for Systemic TherapyCompletedPhase 4AbbVieNCT04908475Written as Apremilast
- Study to Evaluate Safety and Effectiveness of Oral Apremilast (CC-10004) in Patients With Moderate to Severe Plaque PsoriasisCompletedPhase 3AmgenNCT01194219Written as Apremilast
- Study to Evaluate Pharmacokinetics of Prototype Modified-Release Formulations Of Apremilast in Healthy MenCompletedPhase 1AmgenNCT02236988Written as Apremilast Immediate Release
- Efficacy and Safety of Enstilar Foam in Combination With Apremilast (Otezla) in Patients With Moderate Plaque PsoriasisCompletedPhase 4L.H. Kircik, M.D.NCT03441789Written as Otezla
As the comparator · 10 — what is tested is compared with apremilast
- A Study to Evaluate the Efficacy and Safety of ESK-001 in Patients With Moderate to Severe Plaque PsoriasisCompletedPhase 3Alumis IncNCT06586112Written as Apremilast
- A Study in Patients With Moderate to Severe Plaque Psoriasis to Evaluate the Efficacy and Safety of ESK-001CompletedPhase 3Alumis IncNCT06588738Written as Apremilast
- A Study to Determine the Efficacy and Safety of Deucravacitinib Compared With Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Are Naïve to Biologic Disease Modifying Anti-rheumatic Drugs or Had Previously Received TNFα Inhibitor TreatmentActive, not recruitingPhase 3Bristol-Myers SquibbNCT04908189Written as Apremilast
- HPP737 in Adult Patients With Plaque PsoriasisCompletedPhase 3Newsoara Biopharma Co., Ltd.NCT07712731Written as Apremilast
- A Study About How Well TAK-279 Works and Its Safety in Participants With Moderate-to-severe Plaque Psoriasis During 60 Weeks of Treatment With a Withdrawal and Retreatment PeriodCompletedPhase 3TakedaNCT06108544Written as Apremilast
- A Study About How Well TAK-279 Works and Its Safety in Participants With Moderate-to-severe Plaque Psoriasis During 52 Weeks of TreatmentCompletedPhase 3TakedaNCT06088043Written as Apremilast
- Effectiveness and Safety of BMS-986165 Compared to Placebo and Active Comparator in Participants With PsoriasisCompletedPhase 3Bristol-Myers SquibbNCT03624127Written as Apremilast
- An Investigational Study to Evaluate Experimental Medication BMS-986165 Compared to Placebo and a Currently Available Treatment in Participants With Moderate-to-Severe Plaque PsoriasisCompletedPhase 3Bristol-Myers SquibbNCT03611751Written as Apremilast
- CF101 Therapy in Patients With Moderate-to-severe Plaque PsoriasisCompletedPhase 3Can-Fite BioPharmaNCT03168256Written as Apremilast 30mg
- A Study of LY2775240 in Healthy ParticipantsCompletedPhase 1Eli Lilly and CompanyNCT02963779Written as Apremilast
What changed recently
From the registry's own updates since Oct 18, 2026.
Newly registered1
Codes
What other systems call apremilast · ClinicalTrials.gg INT004838
- MeSH (NLM) C505730apremilastConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) UP7QBP99PNAPREMILASTConfirmed FDA, NLM, Wikidata
- RxNorm 1492727Confirmed FDA, Wikidata
- Wikidata Q2858961apremilastConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C147044ApremilastOne source FDA
- DrugBank DB05676One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C505730 | apremilast | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | UP7QBP99PN | APREMILAST | Confirmed FDA, NLM, Wikidata |
| RxNorm | 1492727 | — | Confirmed FDA, Wikidata |
| Wikidata | Q2858961 | apremilast | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C147044 | Apremilast | One source FDA |
| DrugBank | DB05676 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.